Preclinical study has further underscored the potential value of Akt inhibitors in multiple types of cancer, including head and neck cancer (NCT01349933), pancreatic cancer (NCT01783171), and ovarian cancer (NCT01283035). This evidence concerns the gene AKT1 and familial pancreatic carcinoma.